Bevacizumab (Avastin™) Improves Survival in Metastatic Colorectal Cancer
Patients with newly diagnosed metastatic colon cancer who received the therapeutic agent bevacizumab (Avastin™) along with the chemotherapy combination known as IFL had substantially longer overall survival times than patients who received IFL but with a placebo instead of bevacizumab. With these results, bevacizumab becomes the first anti-angiogenesis agent to prove effective in a randomized Phase III trial.
FDA Approves Erbitux for Colorectal Cancer
Erbitux (cetuximab) is the first monoclonal antibody approved to treat patients with advanced colorectal cancer that has spread to other parts of the body.
Oxaliplatin-Based Regimen Prolongs Survival After Colorectal Cancer Surgery
The oxaliplatin-based chemotherapy combination known as FOLFOX significantly improved disease-free survival compared to 5-FU and leucovorin when used as adjuvant therapy (after surgery) in patients with stage II and stage III colorectal cancer.
Older Patients with Colon Cancer Benefit from Chemotherapy
Adjuvant (additional) chemotherapy for colon cancer is equally effective and no more
toxic in otherwise healthy patients age 70 and older than in younger patients,
according to research published in the October 11, 2001, issue of New England
Journal of Medicine.